As part of the deal, CANbridge secures exclusive rights to commercialize Caphosol in China, where over 3.5 million new cancer cases are diagnosed each year.
CANbridge founder and CEO James Xue said Caphosol represents the second oncology product the company will commercialize in China and will meet a severely underserved medical need in China.
"Our agreement with EUSA Pharma represents our strategy of partnering with Western companies to commercialize treatments that will profoundly improve quality-of-life for patients in China and North Asia," Xue said.
"With the addition of Caphosol and other follow-on products, CANbridge is expanding its footprint in oncology and will evolve into a commercial- stage company in the foreseeable future."
Caphosol is designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx.
In the US, the device is indicated for dryness of the mouth or throat and as an adjunct to standard oral care in treating the mucositis that may be caused by radiation or high dose chemotherapy.
Within the EU, Caphosol is indicated for the above as well as an adjunct to standard oral care in the prevention of the mucositis that may be caused by radiation or high dose chemotherapy.
